Beyond PD‐1: Mechanisms of Resistance to Checkpoint Blockade in Classical Hodgkin Lymphoma and Next‐Generation Immune Strategies
European Journal of Haematology · 2026-04 · 116 (4) · 357-367
DOI: 10.1111/ejh.70101 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Journal of Haematology, online erschienen am 25.12.2025. Verfasst von Santino Caserta und 12 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Unit, Department of Onco-Hematology, AO of Cosenza, Cosenza, Italy. Hauptthemen laut MEDLINE: Hodgkin Disease, Immune Checkpoint Inhibitors, Programmed Cell Death 1 Receptor, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
PD‐1 inhibitors have reshaped the treatment landscape of classical Hodgkin lymphoma, yet a substantial proportion of patients exhibit primary or acquired resistance driven by tumor‐intrinsic alterations, immunosuppressive microenvironmental signals, metabolic constraints, and EBV‐mediated modulation. This review summarizes key mechanisms underlying PD‐1 resistance and highlights emerging biomarkers—including early 18 F‐FDG PET response, circulating tumor DNA kinetics, molecular subtyping, and spatial immune profiling—that enable early identification of nonresponders and support precision immunotherapy. Novel therapeutic strategies such as macrophage‐targeted agents, metabolic modulators, bispecific antibodies, low‐dose PD‐1 regimens, and CD30‐directed CAR‐T cells show promise in overcoming resistance, particularly when integrated into adaptive, biomarker‐guided treatment algorithms. Early incorporation of PET and ctDNA monitoring may inform timely treatment adaptation, while combination approaches addressing macrophage‐driven suppression or redundant immune checkpoints should be considered in biologically high‐risk patients. Overall, a deeper mechanistic understanding coupled with biomarker‐driven stratification is essential to optimize PD‐1‐based therapy and improve long‐term outcomes in cHL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hematology Unit, Department of Onco-Hematology, AO of Cosenza, Cosenza, Italy.
- Emergency and Internal Medicine Department, Saint Joseph Hospital, East Jerusalem, Palestine.
- Department of Experimental and Clinical Medicine, University of Catanzaro, Catanzaro, Italy.
- AIL Sezione di Cosenza, Cosenza, Italy.
- Department of Pharmacy, Health and Nutritional Science, University of Calabria, Rende, Italy.
ORCID-Profile: Francesco Mendicino, Massimo Gentile
Zitieren
APA
Caserta, S., Martino, E. A., Skafi, M., Alvaro, M. E., Bruzzese, A., Amodio, N., Lucia, E., Olivito, V., Labanca, C., Mendicino, F., Vigna, E., Morabito, F., & Gentile, M. (2026). Beyond PD‐1: Mechanisms of Resistance to Checkpoint Blockade in Classical Hodgkin Lymphoma and Next‐Generation Immune Strategies. European Journal of Haematology, 116(4), 357-367. https://doi.org/10.1111/ejh.70101
Vancouver
Caserta S, Martino EA, Skafi M, Alvaro ME, Bruzzese A, Amodio N, et al. Beyond PD‐1: Mechanisms of Resistance to Checkpoint Blockade in Classical Hodgkin Lymphoma and Next‐Generation Immune Strategies. European Journal of Haematology. 2026;116(4):357-367. doi:10.1111/ejh.70101
BibTeX
@article{Caserta2026,
author = {Caserta, Santino and Martino, Enrica Antonia and Skafi, Mamdouh and Alvaro, Maria Eugenia and Bruzzese, Antonella and Amodio, Nicola and Lucia, Eugenio and Olivito, Virginia and Labanca, Caterina and Mendicino, Francesco and Vigna, Ernesto and Morabito, Fortunato and Gentile, Massimo},
title = {Beyond PD‐1: Mechanisms of Resistance to Checkpoint Blockade in Classical Hodgkin Lymphoma and Next‐Generation Immune Strategies},
journal = {European Journal of Haematology},
year = {2026},
volume = {116},
number = {4},
pages = {357--367},
doi = {10.1111/ejh.70101}
}
EUVIMED